Single Port Insulin Infusion for Improved Diabetes Management
Existing therapeutic devices for diabetic patients suffer from bulky size, inaccurate measurements and the difficulties of handling two body interfaces. Suboptimal control of blood glucose levels in type 1 or type 2 diabetes melli...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTI2018-095180-B-I00
SISTEMA ADAPTATIVO BIOINSPIRADO PARA EL CONTROL GLUCEMICO BA...
106K€
Cerrado
PDC2021-121470-C21
PREDICCION DE GLUCOSA SIN INTERVENCION DEL USUARIO PARA EL A...
69K€
Cerrado
PDC2021-121470-C22
HERRAMIENTA DE APRENDIZAJE AUTOMATICO QUE MINIMIZA EL RIESGO...
69K€
Cerrado
INSULYNC
INSULYNC Changing the way diabetes is treated
71K€
Cerrado
CPP2021-008659
Hacia una nueva generación de soluciones digitales para la d...
275K€
Cerrado
WASP
Wide Spectral Range Photonic Glucometer
150K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Existing therapeutic devices for diabetic patients suffer from bulky size, inaccurate measurements and the difficulties of handling two body interfaces. Suboptimal control of blood glucose levels in type 1 or type 2 diabetes mellitus patients results in periods of hypo- and hyperglycaemia leading to severe and life-threatening complications. Exploiting a novel glucose sensor technology, SPIDIMAN aims to improve glycaemic management for better quality of life and healthier aging. The consortium will develop a new coating technology to apply a glucose-sensitive fluorescent dye onto a standard insulin catheter and incorporate this integrated glucose sensor into a single-port artificial pancreas system. Advanced optical continuous glucose monitoring technology (smart tattoos) with improved sensor accuracy, faster response times, wider dynamic range and higher signal stability will advance diabetes management by reducing hypo- and hyperglycaemic episodes. Within SPIDIMAN, research-intensive European SMEs will develop an innovative artificial pancreas approach, and experienced participants will perform clinical validation in a European network of specialised diabetes centres. SPIDIMAN will thus pave the way for a single-port device that integrates improved glucose measurement and more accurate insulin delivery to provide better glycaemic management in patients with insulin-dependent diabetes. The new device is expected to be particularly suitable for patients in childhood and adolescence, who will form a special focus of the project.